Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EKLQ | ISIN: US1569441009 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:59
26,880 US-Dollar
+0,94 % +0,250
1-Jahres-Chart
CG ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
CG ONCOLOGY INC 5-Tage-Chart

Aktuelle News zur CG ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CG ONCOLOGY Aktie jetzt für 0€ handeln
FrCG Oncology, Inc. - 8-K, Current Report1
22.05.CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success2
13.05.CG Oncology, Inc. GAAP EPS of $0.451
13.05.CG Oncology, Inc. - 10-Q, Quarterly Report1
13.05.CG Oncology, Inc. - 8-K, Current Report-
13.05.CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates291- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal...
► Artikel lesen
02.05.JPMorgan sets CG Oncology stock overweight, $41 target5
29.04.UBS maintains CG Oncology stock Buy rating, $60 target3
29.04.Why CG Oncology, Inc. (CGON) Surged on Monday1
28.04.CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why1
28.04.CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug3
28.04.Cantor Fitzgerald maintains CG Oncology stock with $75 target4
28.04.CG Oncology, Inc. - 8-K, Current Report1
26.04.CG Oncology Inc.: CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting211- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C - - 58.3% of patients showed durable complete responses by K-M at 24 months - - 97.3% of...
► Artikel lesen
31.03.HC Wainwright maintains CG Oncology stock Buy rating, $75 target16
28.03.CG Oncology announces mixed shelf offering3
28.03.CG Oncology, Inc. GAAP EPS of -$0.462
28.03.CG Oncology, Inc. - 10-K, Annual Report-
28.03.CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates281- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated...
► Artikel lesen
25.03.Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts1
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1